$MRSN
Mersana Therapeutics, Inc. Stock $mrsn

$mrsn Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000162828024021985 Filed on May 09, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$2.293M	$9.245M
YoY Change	-78.48%	18.5%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$10.50M	$11.56M
YoY Change	-42.25%	-36.93%
% of Gross Profit
Research & Development	$17.25M	$18.69M
YoY Change	-64.78%	-60.47%
% of Gross Profit
Depreciation & Amortization	$403.0K	$423.0K
YoY Change	24.38%	32.6%
% of Gross Profit
Operating Expenses	$27.75M	$30.25M
YoY Change	-58.68%	-53.9%
Operating Profit
YoY Change
Interest Expense	$1.187M	$1.002M
YoY Change	15.8%	1.93%
% of Operating Profit
Other Income/Expense, Net	$1.187M	$1.695M
YoY Change	-45.9%	3.48%
Pretax Income	-$24.27M	-$19.31M
YoY Change	-55.31%	-65.63%
Income Tax
% Of Pretax Income
Net Earnings	-$24.30M	-$19.30M
YoY Change	-55.25%	-65.66%
Net Earnings / Revenue	-1059.75%	-208.76%
Basic Earnings Per Share	-$0.20	-$0.16
Diluted Earnings Per Share	-$0.20	-$0.16
COMMON SHARES
Basic Shares Outstanding	122.4M shares	121.3M shares
Diluted Shares Outstanding	122.4M shares	121.4M shares

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$162.7M	$183.1M
YoY Change	-43.21%	-33.14%
Cash & Equivalents	$59.00M	$75.19M
Short-Term Investments	$103.7M	$108.0M
Other Short-Term Assets	$4.651M	$4.392M
YoY Change	-55.7%	-44.32%
Inventory
Prepaid Expenses
Receivables	$1.570M
Other Receivables	$0.00
Total Short-Term Assets	$169.0M	$187.5M
YoY Change	-43.13%	-33.45%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.187M	$10.36M
YoY Change	-31.42%	-24.95%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$978.0K	$478.0K
YoY Change	89.17%	-18.71%
Total Long-Term Assets	$10.17M	$10.84M
YoY Change	-26.94%	-24.69%
TOTAL ASSETS
Total Short-Term Assets	$169.0M	$187.5M
Total Long-Term Assets	$10.17M	$10.84M
Total Assets	$179.1M	$198.4M
YoY Change	-42.4%	-33.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.013M	$3.086M
YoY Change	-82.19%	-83.0%
Accrued Expenses	$17.78M	$15.86M
YoY Change	-46.87%	-51.34%
Deferred Revenue	$29.35M	$25.62M
YoY Change	43.15%	-10.95%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$8.333M	$5.208M
YoY Change
Total Short-Term Liabilities	$62.18M	$53.41M
YoY Change	-17.0%	-35.97%
LONG-TERM LIABILITIES
Long-Term Debt	$17.05M	$19.79M
YoY Change	-31.8%	-20.83%
Other Long-Term Liabilities	$626.0K	$638.0K
YoY Change	723.68%	355.71%
Total Long-Term Liabilities	$17.68M	$20.43M
YoY Change	-29.51%	-18.74%
TOTAL LIABILITIES
Total Short-Term Liabilities	$62.18M	$53.41M
Total Long-Term Liabilities	$17.68M	$20.43M
Total Liabilities	$170.7M	$170.4M
YoY Change	-22.83%	-26.53%
SHAREHOLDERS EQUITY
Retained Earnings	-$869.9M	-$845.7M
YoY Change	13.68%	18.96%
Common Stock	$878.4M	$873.7M
YoY Change	2.74%	12.72%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.427M	$27.99M
YoY Change
Total Liabilities & Shareholders Equity	$179.1M	$198.4M
YoY Change	-42.4%	-33.03%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	-$24.30M	-$19.30M
YoY Change	-55.25%	-65.66%
Depreciation, Depletion And Amortization	$403.0K	$423.0K
YoY Change	24.38%	32.6%
Cash From Operating Activities	-$21.86M	-$32.66M
YoY Change	-64.66%	12.59%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$132.0K
YoY Change	-100.0%	-85.51%
Acquisitions
YoY Change
Other Investing Activities	$5.514M	-$72.42M
YoY Change	-209.4%	-3238.93%
Cash From Investing Activities	$5.514M	-$72.55M
YoY Change	-201.38%	-5296.78%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	153.0K	$5.829M
YoY Change	-99.79%	-72.95%
NET CHANGE
Cash From Operating Activities	-21.86M	-$32.66M
Cash From Investing Activities	5.514M	-$72.55M
Cash From Financing Activities	153.0K	$5.829M
Net Change In Cash	-16.19M	-$99.38M
YoY Change	-374.05%	1539.85%
FREE CASH FLOW
Cash From Operating Activities	-$21.86M	-$32.66M
Capital Expenditures	$0.00	$132.0K
Free Cash Flow	-$21.86M	-$32.79M
YoY Change	-64.88%	9.6%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	91000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	938000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	53406000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	63637000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4224000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5149000	usd
CY2024Q1	us-gaap	Long Term Debt LongTermDebt	20098000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	23148000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	92022000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	97167000	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	638000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	55000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	170388000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	189156000	usd
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	27985000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	36904000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	198373000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	226060000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9245000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7802000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	122359130	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	122359130	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	12000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	12000	usd
CY2024Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	873730000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	863242000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-90000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	11000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-845667000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-826361000	usd
CY2024Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4392000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4973000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	187538000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	214057000	usd
CY2024Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	3408000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	3831000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6949000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7694000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	478000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	478000	usd
CY2024Q1	us-gaap	Assets Assets	198373000	usd
CY2023Q4	us-gaap	Assets Assets	226060000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	3086000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7319000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15856000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	21898000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	25618000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	28147000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3547000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3252000	usd
CY2024Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	5208000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2083000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18686000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	47275000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11560000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18328000	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	30246000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	65603000	usd
CY2024Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	2697000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	2621000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	1002000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	983000	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1695000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1638000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-19306000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-56163000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-101000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	164000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19407000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-55999000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-19306000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19306000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-56163000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-56163000	usd
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.16
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.16
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.52
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.52
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	121424953	shares
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	121424953	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	107514655	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	107514655	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	92057000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	34000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6407000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	164000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-56163000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	64294000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	36904000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	48000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4660000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-101000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-19306000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-19306000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-56163000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	423000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	319000	usd
CY2024Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1117000	usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1411000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4660000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	6407000	usd
CY2024Q1	mrsn	Noncash Operating Lease Expense NoncashOperatingLeaseExpense	745000	usd
CY2023Q1	mrsn	Noncash Operating Lease Expense NoncashOperatingLeaseExpense	669000	usd
CY2024Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-70000	usd
CY2023Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-152000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-30000000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-580000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-620000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-4166000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4728000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-6042000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-10327000	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-630000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-697000	usd
CY2024Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-7874000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-3302000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-32657000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-29005000	usd
CY2024Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	15000000	usd
CY2023Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	66000000	usd
CY2024Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	87415000	usd
CY2023Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	63693000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	132000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	911000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-72547000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1396000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5846000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	21730000	usd
CY2024Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	48000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	34000	usd
CY2024Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
CY2023Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	150000	usd
CY2024Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	65000	usd
CY2023Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	65000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5829000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	21549000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-99375000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-6060000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	175039000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	129363000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	75664000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	123303000	usd
CY2024Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	169000	usd
CY2024Q1	mrsn	Common Stock Issuance Costs CommonStockIssuanceCosts	65000	usd
CY2023Q1	mrsn	Common Stock Issuance Costs CommonStockIssuanceCosts	66000	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	871000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	791000	usd
CY2024Q1	mrsn	Number Of Additional Preclinical Candidates NumberOfAdditionalPreclinicalCandidates	2	candidate
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-19300000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-56200000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-845700000	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company’s unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenue, expenses and related disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. On an ongoing basis, the Company’s management evaluates its estimates which include, but are not limited to, management’s judgments with respect to the identification of performance obligations and standalone selling prices of those performance obligations within its revenue arrangements, accrued preclinical, manufacturing and clinical expenses, valuation of stock-based awards and income taxes. Actual results could differ from those estimates.</span></div>
CY2024Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	117640000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	147653000	usd
CY2023Q1	mrsn	Contract With Customer Liability Increase ContractWithCustomerLiabilityIncrease	0	usd
CY2023Q1	mrsn	Contract With Customer Liability Decrease ContractWithCustomerLiabilityDecrease	3302000	usd
CY2023Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	144351000	usd
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Off-balance Sheet Risk</span></div>Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. The Company does not believe that it is subject to any significant concentrations of credit risk from these financial instruments. The Company has no financial instruments with off-balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	125314000	usd
CY2024Q1	mrsn	Contract With Customer Liability Increase ContractWithCustomerLiabilityIncrease	1573000	usd
CY2024Q1	mrsn	Contract With Customer Liability Decrease ContractWithCustomerLiabilityDecrease	9247000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	9245000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	5110000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	174561000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	75186000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	128885000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	122825000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	478000	usd
CY2024Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	478000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	478000	usd
CY2023Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	478000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	175039000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	75664000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	129363000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	123303000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss	34512000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	13000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest DebtSecuritiesAvailableForSaleExcludingAccruedInterest	34523000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	15	security
CY2024Q1	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	103100000	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	0	security
CY2024Q1	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossPeriodIncreaseDecrease	0	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Excluding Accrued Interest Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossPeriodIncreaseDecrease	0	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5395000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8807000	usd
CY2024Q1	mrsn	Accrued Research Development And Non Clinical Expenses Current AccruedResearchDevelopmentAndNonClinicalExpensesCurrent	3268000	usd
CY2023Q4	mrsn	Accrued Research Development And Non Clinical Expenses Current AccruedResearchDevelopmentAndNonClinicalExpensesCurrent	3090000	usd
CY2024Q1	mrsn	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	3119000	usd
CY2023Q4	mrsn	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	5063000	usd
CY2024Q1	mrsn	Accrued Manufacturing Expenses Current AccruedManufacturingExpensesCurrent	2518000	usd
CY2023Q4	mrsn	Accrued Manufacturing Expenses Current AccruedManufacturingExpensesCurrent	2566000	usd
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	995000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	936000	usd
CY2024Q1	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	202000	usd
CY2023Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	1047000	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	359000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	389000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15856000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	21898000	usd
CY2024Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	25000000	usd
CY2024Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	5208000	usd
CY2024Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	19792000	usd
CY2024Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	216000	usd
CY2024Q1	us-gaap	Debt Instrument Unamortized Premium DebtInstrumentUnamortizedPremium	522000	usd
CY2024Q1	us-gaap	Long Term Debt LongTermDebt	20098000	usd
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	17996810	shares
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	14736953	shares
CY2024Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	17996810	shares
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	14736953	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10902845	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.42
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2289529	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.02
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	12117	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.21
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	469818	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	8.36
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12710439	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.59
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	6626590	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	8.21
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.60
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.06
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	usd
CY2024Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4660000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6407000	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4660000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6407000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.039
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.036
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y21D
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y25D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.15
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.99
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17996810	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15769504	shares
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001628280-24-021985-index-headers.html	Edgar Link	pending
0001628280-24-021985-index.html	Edgar Link	pending
0001628280-24-021985.txt	Edgar Link	pending
0001628280-24-021985-xbrl.zip	Edgar Link	pending
exhibit31110-qfy2024q1.htm	Edgar Link	pending
exhibit31210-qfy2024q1.htm	Edgar Link	pending
exhibit32110-qfy2024q1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mrsn-20240331.htm	Edgar Link	pending
mrsn-20240331.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
mrsn-20240331_cal.xml	Edgar Link	unprocessable
mrsn-20240331_def.xml	Edgar Link	unprocessable
mrsn-20240331_lab.xml	Edgar Link	unprocessable
mrsn-20240331_pre.xml	Edgar Link	unprocessable
mrsn-20240331_htm.xml	Edgar Link	completed
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MRSN
Mersana Therapeutics, Inc. Stock $mrsn

2024 Q2 Form 10-Q Financial Statement

#000162828024021985 Filed on May 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRSN Mersana Therapeutics, Inc. Stock $mrsn

2024 Q2 Form 10-Q Financial Statement

#000162828024021985 Filed on May 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MRSN
Mersana Therapeutics, Inc. Stock $mrsn